The latest Viatris stock price of $11.29 aligns closely with its two-month support level, signaling strong institutional buying interest around this range. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 13.3% since the latest earnings results. Sales in JANZ are likely to have been adversely impacted by government-driven price regulations in Japan and Australia, as well as by a change in Japan's reimbursement for off-patent brands that accelerated generic conversion. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $310 million. Currently trading at $11.30, Viatris stock price shows tight Bollinger Bands formation, pointing to potential volatility once upcoming FDA approvals are announced.